1Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis[J]. N Eng J Med, 2003, 348(2) : 138-150.
2Povoa P, Mmeida E, Moreira P, et al. C-reactive protein as an indicator of sepsis[J]. Intensive Care Med, 1998, 24(10) : 1052-1056.
3Castelli GP, Pognani C, Meisner M. et al. Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction[J]. Crit Care,2004, 8(4) :234-242.
4Castelli GP, Pognani C, Cita M, et al. Proealeitonin, C-reactive protein, white blood cells and SOFA score in ICU:diagnosis and monitoring of sepsis[J]. Minerva Anestesiol,2006, 72(1/2) :69-80.
5Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock[J]. N Engl J Med, 2001, 345(19) : 1368-1377.
6Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ ATS/SIS international sepsis definitions conference[ J ]. Crit Care Med, 2003, 31(4) : 1250-1256.
7American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis [ J ]. Crit Care Med, 1992, 20(6) :864-874.
8Black S, Kushner I, Samols D. C-reactive Protein[J]. J Biol Chem. 2004, 279(47): 487-490.
9Reny JL, Vuagnat A, Ract C, et al. Diagnosis and follow-up of infections in intensive care patients: value of C-reactive protein compared with other clinical and biological variables[J]. Crit Care Med, 2002,30 (3) : 529-535.
10Hoffmann JN, Vollmar B, Laschke MW, et al. Hydroxyethyt starch (130 ku), but not crystalloid volume support, improves mierocirculation during. nonnotensive endotoxemia[J], Anesthesiology, 2002, 97(2): 460-470.
2NICKEL C H, BING|SSER R, MORGENTHALER N G. The role of copeptin as a diagnostic and prognostic biomarker for risk strati- fication in the emergency department[ J]. BMC Med, 2012, 10: 7.
3KATAN M, MORGENTHALER N, WIDMER I, et al. Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stl~ss level[J]. Neuro Endocrinol Lett, 2008, 29(3) : 341 -346.
4BOECK L, EGGIMANN P, SMYRNIOS N, et al. The Sequential Organ Failure Assessment score and copeptin for predicting surviv- al in ventilator- associated pneumonia[J]. J Crit Care 2012, 27 (5) : 523.
5DU J M, SANG G, JIANG C M, et al. Relationship between plas- ma copeptin levels and complications of community - acquired pneumonia i~a preschool children [ J ]. Peptides, 2013, 45 : 61 - 65.
6WROTEK A, JACKOWSKA T, PAWLIK K. Sodium and copeptin levels in children with comnmnity acquired pneumonia [ J ]. Adv Exp Med Bio|, 2015, 835:31 -36.
7NICKEL C H, BINGISSER R, MORGENTHALER N G. The role of copeptin as a diagnostic and prognostic biomarker for risk strati- fication in the emergency department[J]. BMC Med, 2012, 10: 7.
8BOLIGNANO D, CABASSI A, FIACCADOR1 E, et al. Copeptin ( CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology [ J ]. Clin Chem Lab Med, 2014, 52 (10) : 1447 - 1456.
9KRUGER S, EWIG S, KUNDE J, et al. C - terminal provaso- pressin (copeptin) in patients with eommunity- acquired pneumo- nia - influence of antibiotic pre - treatment : results from the Ger- man competence network CAPNETZ [J]. J Antimicrob Chemoth- er, 2009, 64(1): 159-162.
10DE KRUIF M D, LEMAIRE L C, GIEBELEN I A, et ah The in- fluence of eorticosteroids on the release of novel biomarkers in hu- man endotoxemia[ J]. Intensive Care Med, 2008, 34(3) : 518 - 522.
